Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies Corp reported that its Chief Financial Officer, Kyle Piskel, acquired 61,875 shares of common stock as a grant or award on March 4, 2026. The shares were recorded at a price of $0.00 per share, indicating they were not purchased on the open market but received as compensation. Following this transaction, Piskel directly owned 278,512 shares of Adaptive Biotechnologies common stock.
OWEN KATEY EINTERZ reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp director Katey Einterz Owen received an equity award of 15,625 shares of Common Stock on March 4, 2026. The shares were granted at a price of $0.00 per share, indicating a stock award rather than an open‑market purchase. Following this grant, her directly held Common Stock increased to 88,254 shares, reflecting her updated ownership position as a company director.
Adaptive Biotechnologies Corp director receives stock award
Adaptive Biotechnologies Corp director Michelle Renee Griffin acquired 15,625 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. After this transaction, she directly owns a total of 31,019 shares of the company’s common stock.
Adaptive Biotechnologies Corp reported that CEO and Chairman Chad M. Robins acquired common stock through equity awards. On March 6, 2026, he received 709,220 shares of common stock at a price of $0.00 per share, bringing his direct holdings to 2,771,280 shares after this transaction.
On March 4, 2026, he was also awarded 127,813 shares of common stock at $0.00 per share, resulting in 2,062,060 directly held shares after that earlier transaction. A related footnote explains that these awards stem from performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026, with the issuer certifying that performance goals were achieved and the units vesting on March 6, 2026.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported exercising stock options and selling shares. On the same day, she exercised options for 48,044 shares of common stock at $3.99 per share, then sold 48,044 common shares at a weighted average price of $15.30, with individual trades ranging from $15.11 to $15.54. After these transactions, she directly owned 15,394 common shares. The option was fully vested and exercisable, and the trades were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and related share sales. Over March 3–5, 2026, she exercised fully or partially vested stock options into common stock and sold 92,823 shares in open-market transactions at prices reported around the mid-teens per share.
The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, meaning they followed a prearranged schedule. After these transactions, Rubinstein held 575,235 shares of common stock directly. Reported sale prices are weighted averages of multiple trades, with ranges disclosed between $15.11 and $16.94 per share.
Adaptive Biotechnologies Corp’s Chief Scientific Officer, Harlan S. Robins, reported open-market sales of company common stock under a pre-established Rule 10b5-1 trading plan adopted on August 11, 2025.
He sold 10,000 shares on March 2, 2026 at a weighted average price of $15.72 per share and 14,233 shares on March 3, 2026 at a weighted average price of $16.52 per share. After these sales, he directly owned 1,155,291 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of an aggregate 524,998 shares of common stock in late February and early March 2026 under a Rule 10b5-1 trading plan adopted on August 11, 2025. The shares were sold in multiple transactions at weighted average prices, with sale prices ranging from $15.11 to $16.23 per share. Following these transactions, Robins directly holds 1,934,247 shares of Adaptive Biotechnologies common stock.
ADPT reported Form 144 notice showing proposed sales of Common Stock by Harlan Robins. The filing lists multiple dispositions with trade dates and amounts, including 10,000 shares on 01/06/2026 and 2,395 shares on 02/02/2026.
The filing also records awards acquired as compensation (Restricted Stock Units) on 03/06/2023. The entries show per‑trade counts and dollar values for recent sales; timing and sale method details appear in the transaction lines.
Adaptive Biotechnologies insider sale reported: Chad M. Robins reported multiple sales of Common Stock under Rule 144, with transactions dated between 01/05/2026 and 03/03/2026. The reported lots include individual sales such as 41,666 shares, 99,225 shares, 116,334 shares, and others, each with an accompanying cash amount in USD. The filings list broker details and aggregate per‑lot proceeds; timing and direction are sales as reported.